Prevalence and management of cancer-related anaemia, iron deficiency and the specific role of I.V. iron

Annals of Oncology

Volumn 23, Issue 8, 2012, Pages 1954-1962

  Aapro, M ^a   Osterborg A ^b   Gascon P ^c   Ludwig, H ^d   Beguin, Y ^e  

^a CLINIQUE DE GENOLIER   (Switzerland)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c UNIVERSITY OF BARCELONA   (Spain)

^d WILHELMINEN HOSPITAL   (Austria)

^e UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Anaemia; Chemotherapy induced anaemia; Diagnosis; Hepcidin; Intravenous iron; Iron deficiency

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTHRACYCLINE DERIVATIVE; ANTIANEMIC AGENT; C REACTIVE PROTEIN; FERRIC CARBOXYMALTOSE; FERRIC GLUCONATE; FERRIC HYDROXIDE SUCROSE; FERRITIN; FERUMOXYTOL; HEMOGLOBIN; HEPCIDIN; IRON; IRON DEXTRAN; IRON ISOMALTOSIDE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PLACEBO; PLATINUM COMPLEX; RECOMBINANT ERYTHROPOIETIN; UNCLASSIFIED DRUG;

ANAPHYLAXIS; ANEMIA; BLOOD TRANSFUSION; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER PATIENT; CHRONIC DISEASE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG TOLERABILITY; FERRITIN BLOOD LEVEL; GASTROINTESTINAL DISEASE; HEMOCHROMATOSIS; HUMAN; INFECTION RISK; IRON DEFICIENCY; IRON DEFICIENCY ANEMIA; IRON OVERLOAD; IRON THERAPY; PATIENT COMPLIANCE; PREVALENCE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TUMOR GROWTH;

EID: 84864955819     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds112     Document Type: Review

References (77)

1. Ludwig H, Van BS, Barrett-Lee P et al. The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer 2004; 40: 2293-2306.
2. Beale AL, Penney MD, Allison MC. The prevalence of iron deficiency among patients presenting with colorectal cancer. Colorectal Dis 2005; 7: 398-402.
3. Kuvibidila SR, Gauthier T, Rayford W. Serum ferritin levels and transferrin saturation in men with prostate cancer. J Natl Med Assoc 2004; 96: 641-649.
4. Krayenbuehl PA, Battegay E, Breymann C et al. Intravenous iron for the treatment of fatigue in nonanemic, premenopausal women with low serum ferritin concentration. Blood 2011; 118: 3222-3227.
5. Aapro MS, Link H. September 2007 update on EORTC guidelines and anemia management with erythropoiesis-stimulating agents. Oncologist 2008; 13 (Suppl 3): 33-36.
6. Bokemeyer C, Aapro MS, Courdi A et al. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update. Eur J Cancer 2007; 43: 258-270.
7. National Comprehensive Cancer Network Inc. NCCN Practice Guidelines in Oncology; Cancer and Chemotherapy-Induced Anemia-v.2. 2012; http://www.nccn.org/professionals/physician_gls/PDF/anemia.pdf (5 September 2011, date last accessed).
8. Rizzo JD, Brouwers M, Hurley P et al. American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. Blood 2010; 116: 4045-4059.
9. Auerbach M, Ballard H, Trout JR et al. Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial. J Clin Oncol 2004; 22: 1301-1307.
10. Auerbach M, Silberstein PT, Webb RT et al. Darbepoetin alfa 300 or 500 ug once every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia. Am J Hematol 2010; 85: 655-663.
11. Bastit L, Vandebroek A, Altintas S et al. Randomized, multicenter, controlled trial comparing the efficacy and safety of darbepoetin alpha administered every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia. J Clin Oncol 2008; 26: 1611-1618.
12. Hedenus M, Birgegard G, Nasman P et al. Addition of intravenous iron to epoetin beta increases hemoglobin response and decreases epoetin dose requirement in anemic patients with lymphoproliferative malignancies: a randomized multicenter study. Leukemia 2007; 21: 627-632.
13. Henry DH, Dahl NV, Auerbach M et al. Intravenous ferric gluconate significantly improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy. Oncologist 2007; 12: 231-242.
14. Pedrazzoli P, Farris A, Del PS et al. Randomized trial of intravenous iron supplementation in patients with chemotherapy-related anemia without iron deficiency treated with darbepoetin alpha. J Clin Oncol 2008; 26: 1619-1625.
15. Dangsuwan P, Manchana T. Blood transfusion reduction with intravenous iron in gynecologic cancer patients receiving chemotherapy. Gynecol Oncol 2010; 116: 522-525.
16. Kim YT, Kim SW, Yoon BS et al. Effect of intravenously administered iron sucrose on the prevention of anemia in the cervical cancer patients treated with concurrent chemoradiotherapy. Gynecol Oncol 2007; 105: 199-204.
17. Steinmetz HT, Tsamaloukas A, Schmitz S et al. A new concept for the differential diagnosis and therapy of anaemia in cancer patients. Support Care Cancer 2010; 19: 261-269.
18. Beguin Y, Lybaert W, Bosly A. A prospective observational study exploring the impact of iron status on response to darbepoetin alfa in patients with chemotherapy induced anemia. Blood 2009; 114 (Abstr 2007).
19. Ludwig H, Müldür E, Endler G et al. High prevalence of iron deficiency across different tumors correlates with anemia, increases during cancer treatment and is associated with poor performance status. Haematologica 2011; 96 (Abstr 982).
20. Anker SD, Comin CJ, Filippatos G et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med 2009; 361: 2436-2448.
21. Caro JJ, Salas M, Ward A et al. Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review. Cancer 2001; 91: 2214-2221.
22. Nissenson AR, Wade S, Goodnough T et al. Economic burden of anemia in an insured population. J Manag Care Pharm 2005; 11: 565-574.
23. Crawford J, Cella D, Cleeland CS et al. Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy. Cancer 2002; 95: 888-895.
24. Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med 2005; 352: 1011-1023.
25. Grotto HZ. Anaemia of cancer: an overview of mechanisms involved in its pathogenesis. Med Oncol 2008; 25: 12-21.
26. Fillet G, Beguin Y, Baldelli L. Model of reticuloendothelial iron metabolism in humans: abnormal behavior in idiopathic hemochromatosis and in inflammation. Blood 1989; 74: 844-851.
27. Van Wyck D, Anderson J, Johnson K. Labile iron in parenteral iron formulations: a quantitative and comparative study. Nephrol Dial Transplant 2004; 19: 561-565.
28. Brugnara C, Chambers LA, Malynn E et al. Red blood cell regeneration induced by subcutaneous recombinant erythropoietin: iron-deficient erythropoiesis in ironreplete subjects. Blood 1993; 81: 956-964.
29. Weiss G. Iron metabolism in the anemia of chronic disease. Biochim Biophys Acta 2009; 1790: 682-693.
30. Groopman JE, Itri LM. Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst 1999; 91: 1616-1634.
31. Tas F, Eralp Y, Basaran M et al. Anemia in oncology practice: relation to diseases and their therapies. Am J Clin Oncol 2002; 25: 371-379.
32. Untch M, Mobus V, Kuhn W et al. Intensive dose-dense compared with conventionally scheduled preoperative chemotherapy for high-risk primary breast cancer. J Clin Oncol 2009; 27: 2938-2945.
33. Wish JB. Assessing iron status: beyond serum ferritin and transferrin saturation. Clin J Am Soc Nephrol 2006; 1Suppl 1S4-S8.
34. Beguin Y. Prediction of response and other improvements on the limitations of recombinant human erythropoietin therapy in anemic cancer patients. Haematologica 2002; 87: 1209-1221.
35. Thomas C, Kirschbaum A, Boehm D et al. The diagnostic plot: a concept for identifying different states of iron deficiency and monitoring the response to epoetin therapy. Med Oncol 2006; 23: 23-36.
36. Ludwig H, Endler G, Hübl W et al. High prevalence of iron deficiency in patients with various hematological and malignant diseases: a single center study in 1989 sequential patients. Haematologica 2010; 95 (Abstr 1819).
37. Vamvakas EC, Blajchman MA. Transfusion-related mortality: the ongoing risks of allogeneic blood transfusion and the available strategies for their prevention. Blood 2009; 113: 3406-3417.
38. Marik PE, Corwin HL. Efficacy of red blood cell transfusion in the critically ill: a systematic review of the literature. Crit Care Med 2008; 36: 2667-2674.
39. Thomson A, Farmer S, Hofmann A et al. Patient blood management-a new paradigm for transfusion medicine?. ISBT Science Series 2009; 4: 423-435.
40. Rawn J. The silent risks of blood transfusion. Curr Opin Anaesthesiol 2008; 21: 664-668.
41. Amato AC, Pescatori M. Effect of perioperative blood transfusions on recurrence of colorectal cancer: meta-analysis stratified on risk factors. Dis Colon Rectum 1998; 41: 570-585.
42. Bohlius J, Schmidlin K, Brillant C et al. Erythropoietin or darbepoetin for patients with cancer-meta-analysis based on individual patient data. Cochrane Database Syst Rev 2009; CD007303.
43. Gabrilove JL, Cleeland CS, Livingston RB et al. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol 2001; 19: 2875-2882.
44. Littlewood TJ, Bajetta E, Nortier JW et al. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2001; 19: 2865-2874.
45. Ludwig H, Aapro M, Bokemeyer C et al. Treatment patterns and outcomes in the management of anaemia in cancer patients in Europe: findings from the Anaemia Cancer Treatment (ACT) study. Eur J Cancer 2009; 45: 1603-1615.
46. European Medicines Agency. Summary of scientific discussion. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion_-_Variation/human/000332/WC500026146.pdf (5 September 2011, date last accessed).
47. US Food and Drug Administration. Epoetin Alfa (Marketed as Epoetin, Procrit) Label. http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/103234s5199lbl.pdf (5 September 2011, date last accessed).
48. US Food and Drug Administration. Darbepoetin Alfa (Marketed as Aransep) Label. http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/103951s5197lbl.pdf (5 September 2011, date last accessed).
49. US Food and Drug Administration. FDA Announces New Safety Plan for Agents Used to Treat Chemotherapy-Related Anemia. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2010/ucm200471.htm (5 September 2011, date last accessed).
50. Macdougall IC. Strategies for iron supplementation: oral versus intravenous. Kidney Int Suppl 1999; 69: S61-S66.
51. Steensma DP, Sloan JA, Dakhil SR et al. Phase III, randomized study of the effects of parenteral iron, oral iron, or no iron supplementation on the erythropoietic response to darbepoetin alfa for patients with chemotherapyassociated anemia. J Clin Oncol 2011; 29: 97-105.
52. Gafter-Gvili A, Rozen-Zvi B, Vidal L et al. Intravenous iron supplementation for the treatment of cancer-related anemia-systematic review and meta-analysis. Blood 2010; 116 (Abstr 4249).
53. Petrelli F, Borgonovo K, Cabiddu M et al. Addition of iron to erythropoiesisstimulating agents in cancer patients: a meta-analysis of randomized trials. J Cancer Res Clin Oncol 2012; 138: 179-187.
54. Steensma DP, Sloan JA, Loprinzi CL. Reply to M. Aapro et al. J Clin Oncol 2011; 29: e527-e528.
55. Aapro M, Beguin Y, Birgegard G et al. Too-low iron doses and too many dropouts in negative iron trial?. J Clin Oncol 2011; 29: e525-e526.
56. Steensma DP, Sasu BJ, Sloan JA et al. The relationship between serum hepcidin levels and clinical outcomes in patients with chemotherapy-associated anemia treated in a controlled trial. J Clin Oncol 2011; 29 (Abstr 9031).
57. Hedenus M, Nasman P, Liwing J. Economic evaluation in Sweden of epoetin beta with intravenous iron supplementation in anaemic patients with lymphoproliferative malignancies not receiving chemotherapy. J Clin Pharm Ther 2008; 33: 365-374.
58. Steinmetz T, Tschechne B, Virgin G et al. Ferric carboxymaltose for the correction of cancer- and chemotherapy-associated anemia in clinical practice. Haematologica 2011; 96 (Abstr 983).
59. Evstatiev R, Marteau P, Iqbal T et al. FERGIcor, a randomized controlled trial on ferric carboxymaltose for iron deficiency anemia in inflammatory bowel disease. Gastroenterology 2011; 141: 846-853.
60. Kulnigg S, Stoinov S, Simanenkov V et al. A novel intravenous iron formulation for treatment of anemia in inflammatory bowel disease: the ferric carboxymaltose (FERINJECT) randomized controlled trial. Am J Gastroenterol 2008; 103: 1182-1192.
61. Bailie GR, Horl WH, Verhof JJ. Differences in spontaneously reported hypersensitivity and serious adverse events for intravenous iron preparations: comparison of Europe and North America. Drug Res 2011; 61: 267-275.
62. Bailie GR, Clark JA, Lane CE et al. Hypersensitivity reactions and deaths associated with intravenous iron preparations. Nephrol Dial Transplant 2005; 20: 1443-1449.
63. Chertow GM, Mason PD, Vaage-Nilsen O et al. Update on adverse drug events associated with parenteral iron. Nephrol Dial Transplant 2006; 21: 378-382.
64. European Medicines Agency. Reflection Paper on Non-Clinical Studies for Generic Nanoparticle Iron Medicinal Product Applications. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2011/04/WC500105048.pdf (17 August 2011, date last accessed).
65. Rottembourg J, Kadri A, Leonard E et al. Do two intravenous iron sucrose preparations have the same efficacy?. Nephrol Dial Transplant 2011; 26: 3262-3267.
66. Schellekens H, Klinger E, Muhlebach S et al. The therapeutic equivalence of complex drugs. Regul Toxicol Pharmacol 2011; 59: 176-183.
67. Aronoff GR, Bennett WM, Blumenthal S et al. Iron sucrose in hemodialysis patients: safety of replacement and maintenance regimens. Kidney Int 2004; 66: 1193-1198.
68. Zhang F, Wang W, Tsuji Y et al. Post-transcriptional modulation of iron homeostasis during p53-dependent growth arrest. J Biol Chem 2008; 283: 33911-33918.
69. Baliga R, Zhang Z, Baliga M et al. In vitro and in vivo evidence suggesting a role for iron in cisplatin-induced nephrotoxicity. Kidney Int 1998; 53: 394-401.
70. Minotti G, Menna P, Salvatorelli E et al. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 2004; 56: 185-229.
71. Toyokuni S. Role of iron in carcinogenesis: cancer as a ferrotoxic disease. Cancer Sci 2009; 100: 9-16.
72. Hasinoff BB, Patel D, O'Hara KA. Mechanisms of myocyte cytotoxicity induced by the multiple receptor tyrosine kinase inhibitor sunitinib. Mol Pharmacol 2008; 74: 1722-1728.
73. Kamba T, McDonald DM. Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer 2007; 96: 1788-1795.
74. Bergeron RJ, Streiff RR, Elliott GT. Influence of iron on in vivo proliferation and lethality of L1210 cells. J Nutr 1985; 115: 369-374.
75. Carthew P, Nolan BM, Smith AG et al. Iron promotes DEN initiated GST-P foci in rat liver. Carcinogenesis 1997; 18: 599-603.
76. Auerbach M, Glaspy J. What is the right balance between iron and erythropoiesis stimulating agents in chemotherapy induced anemia?. Eur J Clin Med Oncol 2009; 1: 7-12.
77. Beguin Y, Maertens J, De Prijck B et al. Darbepoetin-alfa and i.v. iron administration after autologous hematopoietic stem cell transplantation: a prospective randomized multicenter trial. Blood 2008; 112: (Abstr 54).